Acute Lymphoblastic Leukemia (ALL): What to Know

Three words, three pieces of information.

Acute means the cells are immature and multiply fast. Untreated, ALL can go from first symptom to serious illness in weeks. That is why it is treated as an emergency and not scheduled for next month.

Lymphoblastic points to the cell of origin. A lymphoblast is an early lymphocyte, the white cell type that makes up the immune system. In ALL these blasts stall in their immature form and pile up in the marrow, crowding out red cells, platelets, and normal white cells.

Leukemia means the disease lives in the blood and marrow rather than forming a lump.

ALL is uncommon in the whole population but is the classic childhood leukemia. The American Cancer Society projected about 6,250 new US cases and 1,600 deaths for 2026, figures SEER reprints. SEER's own measurements put the median age at diagnosis at 18 and the median age at death at 60. That gap tells you something important: outcomes are much better in children and young adults than in older adults.

Diagnosis usually starts with a complete blood count that looks wrong: low red cells, low platelets, and a white count that may be very high or very low. Blasts often show up on the smear.

Then comes a bone marrow aspirate and biopsy, usually from the back of the hip bone. That sample goes for several separate tests:

• Flow cytometry reads the proteins on the cell surface and sorts B-cell ALL from T-cell ALL.
• Cytogenetics looks at whole chromosomes for changes such as the Philadelphia chromosome or the t(4;11) translocation.
• Molecular testing looks at specific genes, including BCR::ABL1.
• A lumbar puncture samples spinal fluid to see if the leukemia has reached the brain and spinal cord.

Ask which of these are back and which are pending. The chromosome results often take a week and can change the plan.

When a large number of leukemia cells die quickly, they dump their contents into the blood. Potassium, phosphate, and uric acid all rise, and the kidneys can fail. This is tumor lysis syndrome.

It is prevented, not just watched. Expect heavy IV fluids and frequent blood chemistry checks. Allopurinol lowers new uric acid production. Rasburicase (Elitek) breaks down uric acid that is already there. It is given by vein as a short daily infusion for up to 5 days, at an amount the team works out from your weight. Rasburicase is contraindicated in G6PD deficiency, because it can cause severe red cell breakdown, so people from at-risk backgrounds may be screened first.

The brain and spinal cord are what oncologists call a sanctuary site. Most chemotherapy given by vein does not cross into the spinal fluid well. Leukemia cells that reach that space survive treatment and later come back.

So ALL treatment includes central nervous system therapy for everyone, not just for people whose spinal fluid was positive. It is delivered as intrathecal chemotherapy, meaning methotrexate or cytarabine injected directly into the spinal fluid by lumbar puncture, and as high-dose systemic methotrexate that reaches the fluid. Cranial radiation is still used in some cases.

Treatment is divided into remission induction, CNS preventive therapy, and consolidation, which is also called continuation or maintenance. Total treatment length averages 1.5 to 3 years.

That length surprises people. The intense hospital part is measured in weeks. The maintenance part, usually daily and weekly oral drugs, runs for years, and stopping early raises relapse risk.

Growth factor support during induction shortens the time until blood counts recover, and many protocols include it.

The Philadelphia chromosome is a swap between chromosomes 9 and 22 that fuses two genes into BCR::ABL1. The fused gene makes an always-on enzyme that drives cell division. It gets more common with age, which is one reason older adults with ALL have done worse.

It is also treatable in a specific way. Tyrosine kinase inhibitors, taken as pills, switch that enzyme off. Imatinib, nilotinib, and dasatinib are all used, added to chemotherapy and continued through consolidation. Anyone with ALL should know their Philadelphia status.

Two groups do not do well on standard ALL protocols. B-cell ALL with surface immunoglobulin, also called L3 or Burkitt-type, and ALL with the t(4;11) translocation both need something else. For the Burkitt-type disease, short bursts of very intense lymphoma-style chemotherapy completed within about 6 months turned a survival rate of zero in one early study into roughly 50 percent.

Options after relapse now include several targeted immune drugs.

Blinatumomab links a T cell to a CD19 protein on the leukemia cell so the T cell kills it. In a randomized trial against four standard salvage chemotherapy regimens, remission rates were 43.9 percent with blinatumomab versus 24.6 percent, and median overall survival was 7.7 versus 4.0 months.

Inotuzumab ozogamicin is an antibody carrying a toxin to CD22.

Tisagenlecleucel (Kymriah) is a CD19-directed CAR T-cell therapy. Your own T cells are collected, engineered, and given back. Its FDA label covers patients up to 25 years of age with B-cell precursor ALL that is refractory or in second or later relapse.

These are often used as a bridge to an allogeneic stem cell transplant rather than as the final step.

• Temperature 100.4 F (38 C) or higher, or shaking chills
• Bleeding that will not stop, a new rash of tiny red dots, or blood in urine or stool
• Confusion, a severe new headache, or a seizure
• No urine for 8 hours, or sudden swelling
• Chest pain or breathlessness at rest

Leukemia, Blood and Marrow Stem Cell Transplant, CAR T-Cell Therapy, and What Does Minimal Residual Disease Mean.

• https://www.cancer.gov/types/leukemia/hp/adult-all-treatment-pdq
• https://seer.cancer.gov/statfacts/html/alyl.html
• https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0ae10bc4-6b65-402f-9db5-2d7753054922
• https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aad3ba54-dfd3-4cb3-9e2b-c5ef89559189